Authors: Sharon Salt, Editor
NICE has announced today (29 June) that they are provisionally deciding not to recommend ocrelizumab for patients with primary progressive multiple sclerosis (PPMS) on the NHS. This is the first stage of their review process into this new MS treatment.
Ocrelizumab has been licensed to treat both patients with relapsing and early PPMS by the EMA earlier this year in January. Last week, in a reversal of an earlier decision, NICE announced that they approved ocrelizumab for relapsing–remitting MS (RRMS) in England and Wales.